Table 3.
Comparison of survival benefit of candidate JUNV therapeutics in the guinea pig model
| Treatment | Timing of first dose with respect to challenge | Dose (per kg) | Dose frequency | Survival in treated | Survival in controls | Ref. |
| Ribavirin | +4 h | 60 mg | Daily for 24 d | 3/6 | 0/5 | 7 |
| Favipiravir | +1 d | 300 mg (oral) | 2x/day for 14 d | 2/10 | 0/10 | 8 |
| +2 d | 300 mg | 2x/day for 14 d | 7/9 | 1/9 | ||
| Cyclophosphamide | +3 d | 50/25 mg | +3 d/+10 d | 3/18 | 0/18 | 6 |
| Convalescent serum | +6 d | 30,000 TU* | Once | 6/6 | 0/20 | 9 |
| J199 | +6 d | 25 mg | +6/+10 d | 6/6 | 0/3 | |
| +7 d | 25 mg | +7/+11 d | 11/12 | 0/9 |
*
No less then 3,000 TU/kg is the recommended clinical dose (4). Dosing and challenge are all i.p. unless otherwise noted. Data are not comprehensive but rather highlight the best efficacy demonstrated by the treatment. Antibody-based treatments are highlighted in bold.